ACTICOR BIOTECH SAS |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.39 EUR | -4.88% |
|
-89.79% | -86.55% |
| Apr. 30 | Acticor Biotech SAS Announces Postponement in Publication of 2023 Annual Results | CI |
| Apr. 26 | Acticor Biotech: rebound from the previous day's tumble | CF |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Capitalization 1 | 48.3 | 74.16 | 5.123 | 5.123 | - |
| Enterprise Value (EV) 1 | 39.66 | 75.43 | 10.32 | 15.92 | -0.5775 |
| P/E ratio | -2.83 x | -4.74 x | -0.33 x | -0.46 x | 0.38 x |
| Yield | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | - | - |
| EV / Revenue | - | - | - | - | - |
| EV / EBITDA | - | - | -0.67 x | -1.2 x | -0.03 x |
| EV / FCF | - | - | -0.67 x | -1.2 x | -0.03 x |
| FCF Yield | - | - | -149% | -83.5% | -2,874% |
| Price to Book | - | - | -0.7 x | -0.47 x | 1.77 x |
| Nbr of stocks (in thousands) | 10,546 | 10,505 | 13,135 | 13,135 | - |
| Reference price 2 | 4.580 | 7.060 | 0.3900 | 0.3900 | 0.3900 |
| Announcement Date | 3/30/22 | 3/23/23 | - | - | - |
1EUR in Million2EUR
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - |
| EBITDA 1 | - | - | -15.4 | -13.3 | 19.5 |
| EBIT 1 | -11.89 | -15.12 | -15.5 | -13.4 | 19.4 |
| Operating Margin | - | - | - | - | - |
| Earnings before Tax (EBT) | - | - | - | - | - |
| Net income 1 | -12.61 | -15.88 | -15.5 | -13.4 | 16.4 |
| Net margin | - | - | - | - | - |
| EPS 2 | -1.620 | -1.490 | -1.180 | -0.8500 | 1.040 |
| Free Cash Flow 1 | - | - | -15.4 | -13.3 | 16.6 |
| FCF margin | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | 85.13% |
| FCF Conversion (Net income) | - | - | - | - | 101.22% |
| Dividend per Share | - | - | - | - | - |
| Announcement Date | 3/30/22 | 3/23/23 | - | - | - |
1EUR in Million2EUR
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Net Debt 1 | - | 1.26 | 5.2 | 10.8 | - |
| Net Cash position 1 | 8.64 | - | - | - | 5.7 |
| Leverage (Debt/EBITDA) | - | - | -0.3377 x | -0.812 x | - |
| Free Cash Flow 1 | - | - | -15.4 | -13.3 | 16.6 |
| ROE (net income / shareholders' equity) | -198% | - | - | - | 483% |
| ROA (Net income/ Total Assets) | - | - | - | - | - |
| Assets 1 | - | - | - | - | - |
| Book Value Per Share 2 | - | - | -0.5600 | -0.8300 | 0.2200 |
| Cash Flow per Share 2 | -1.770 | -1.150 | -1.170 | -0.8500 | 1.050 |
| Capex 1 | - | - | - | - | - |
| Capex / Sales | - | - | - | - | - |
| Announcement Date | 3/30/22 | 3/23/23 | - | - | - |
1EUR in Million2EUR
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
SELL
Number of Analysts
1
Last Close Price
0.39
EUR
Average target price
1
EUR
Spread / Average Target
+156.41%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -86.55% | 5.48M | |
| -1.17% | 102B | |
| +2.87% | 96.09B | |
| +2.13% | 22.28B | |
| -14.77% | 21.4B | |
| -8.79% | 18.14B | |
| -39.98% | 17.02B | |
| -13.21% | 16.09B | |
| +8.55% | 13.83B | |
| +35.75% | 11.97B |
- Stock Market
- Equities
- ALACT Stock
- Financials Acticor Biotech SAS
